The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | The evolving treatment landscape in PV
In this video, Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly comments on the treatment landscape in polycythemia vera (PV), highlighting its rapid evolution with the advent of novel agents and the collation of new evidence on well-established therapies. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the way we treat PV is going to change remarkably in the next few years. We have a lot of new therapies and we have old therapies that are showing us new evidence.
So interferons, ropeginterferon as an example, clearly is superior to hydroxyurea in terms of controlling counts, but also in reducing the allele fraction, which seems to associate with reductions in event-free survival...
I think the way we treat PV is going to change remarkably in the next few years. We have a lot of new therapies and we have old therapies that are showing us new evidence.
So interferons, ropeginterferon as an example, clearly is superior to hydroxyurea in terms of controlling counts, but also in reducing the allele fraction, which seems to associate with reductions in event-free survival. With ruxolitinib, we have very recent data that shows the same thing, that patients on ruxolitinib seem to have better event-free survival, and that, in fact, as the allele burden reduces, the likelihood of that response improves.
We have rusfertide and other agents like it that are going into clinical trials now that could eliminate phlebotomy needs in many patients. So this landscape is rapidly evolving.
Read more...
